Should Investors Buy SOLV as Growth Improves but Debt Risks Persist?

Solventum Corporation SOLV is showing better underlying growth, a higher earnings outlook and progress on cost reduction. Those trends improve the operating case after a period dominated by separation work.

The decision is less straightforward for investors. Temporary enterprise resource planning (ERP)-related advance orders and tariff refunds boosted second-quarter results, while a sizable debt load and a possible 2027 raw-material cost increase could restrain financial flexibility and future margin gains.

SOLV's Growth Drivers Strengthen

Normalized organic growth was about 4% in the second quarter after adjusting for ERP advance orders and stock-keeping unit (SKU) exits. Advanced Wound Care grew 7.1% organically, Acera advanced 48% year over year and Health Information Systems organic growth reached 5.4%.

Innovation adds another layer. Solventum expects almost 20 product launches through the first quarter of 2028, including Advanced Wound Care products in the first half of 2027. Medtronic plc MDT, a global healthcare technology company, is also investing in new surgical technologies, keeping innovation execution important across the sector.

Image Source: Zacks Investment Research

Solventum's Cost Program Could Lift Margins

Transform for the Future targets about $500 million in annual cost savings through operating efficiencies, procurement, supply-chain changes, system streamlining and automation. Most benefits are expected in 2027 and beyond, giving Solventum a potential path to better margins as the program scales.

The separation from former parent 3M Company MMM is also moving forward. Solventum had exited nearly 70% of roughly 200 transition service agreements and migrated about 950 of 1,200 systems by the second quarter, with separation costs expected to decline beginning in the fourth quarter.

SOLV's Debt Load Limits Flexibility

The balance sheet remains the clearest constraint. Solventum ended the second quarter with $403 million in cash and cash equivalents, compared with $506 million of short-term borrowings and the current portion of long-term debt. Long-term debt was $4.57 billion.

Management reported net debt of $4.7 billion and continues to emphasize debt reduction within its capital plan. Even with improving operating performance, the debt burden reduces room for error while Solventum funds transformation work, separation activities, acquisitions and shareholder returns.

Solventum's 2026 Outlook Has Caveats

Solventum raised adjusted earnings guidance to $7.10-$7.20 per share and lifted its organic sales growth range to 2.5%-3%. Excluding an expected 100-basis-point drag from SKU exits, organic growth is projected to be in the range of 3.5%-4%.

The quality of that outlook still matters. About $125 million of second-quarter sales came from ERP advance orders, with most of the benefit expected to reverse in the third quarter. Tariff refunds also aided margins, while a 2027 3M raw-material pricing option could create a 100-basis-point margin headwind if exercised.

Image Source: Zacks Investment Research

SOLV's Style Scores Support a Balanced View

The operating trend is improving, but the stock does not present a clear buy case yet. Growth drivers and cost actions are moving in the right direction, while debt, temporary second-quarter benefits and unresolved raw-material pricing risk argue for patience.

SOLV currently carries a Zacks Rank #4 (Sell). Its Value Score of B and VGM Score of B are favorable, while its Growth Score of C and Momentum Score of C are more neutral. Because Style Scores complement rather than override the Zacks Rank, the current combination supports a wait-and-see stance despite improving fundamentals.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research